Novavax, Inc.

NASDAQ (USD): Novavax, Inc. (NVAX)

Last Price

5.86

Today's Change

-0.335 (5.40%)

Day's Change

5.81 - 6.16

Trading Volume

2,233,492

Overview

Market Cap

965 Million

Shares Outstanding

160 Million

Avg Volume

4,756,246

Avg Price (50 Days)

7.38

Avg Price (200 Days)

10.03

PE Ratio

-4.88

EPS

-1.23

Earnings Announcement

08-May-2025

Previous Close

6.20

Open

6.12

Day's Range

5.81 - 6.155

Year Range

3.9 - 23.86

Trading Volume

4,870,672

Price Change Highlight

1 Day Change

-3.23%

5 Day Change

0.00%

1 Month Change

-22.28%

3 Month Change

-31.90%

6 Month Change

-41.06%

Ytd Change

-29.99%

1 Year Change

47.42%

3 Year Change

-88.82%

5 Year Change

-74.79%

10 Year Change

-96.38%

Max Change

-92.50%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment